nodes	percent_of_prediction	percent_of_DWPC	metapath
Raltegravir—UGT1A1—Erlotinib—pancreatic cancer	0.275	0.525	CbGbCtD
Raltegravir—UGT1A1—Irinotecan—pancreatic cancer	0.248	0.474	CbGbCtD
Raltegravir—CCR1—Peptide GPCRs—SSTR3—pancreatic cancer	0.00664	0.0354	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—SSTR1—pancreatic cancer	0.00636	0.0339	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—SSTR2—pancreatic cancer	0.00613	0.0327	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—CCKBR—pancreatic cancer	0.00592	0.0315	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—CCKAR—pancreatic cancer	0.00441	0.0235	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—PRLHR—pancreatic cancer	0.00367	0.0196	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—SSTR3—pancreatic cancer	0.00312	0.0166	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—SSTR1—pancreatic cancer	0.00299	0.016	CbGpPWpGaD
Raltegravir—CCR1—Peptide GPCRs—AGTR1—pancreatic cancer	0.00297	0.0158	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—PPY—pancreatic cancer	0.00294	0.0157	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—SSTR2—pancreatic cancer	0.00288	0.0154	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—PRLHR—pancreatic cancer	0.00287	0.0153	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCKBR—pancreatic cancer	0.00278	0.0148	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—SSTR3—pancreatic cancer	0.00263	0.014	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—SSTR1—pancreatic cancer	0.00253	0.0135	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—PPY—pancreatic cancer	0.00248	0.0132	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.00246	0.0131	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—SSTR3—pancreatic cancer	0.00244	0.013	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—SSTR2—pancreatic cancer	0.00243	0.013	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—SSTR1—pancreatic cancer	0.00234	0.0125	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—SSTR2—pancreatic cancer	0.00226	0.012	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CCKBR—pancreatic cancer	0.00218	0.0116	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCK—pancreatic cancer	0.00216	0.0115	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.00209	0.0112	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CCKAR—pancreatic cancer	0.00207	0.0111	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.00201	0.0107	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.00197	0.0105	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—FGF13—pancreatic cancer	0.00194	0.0103	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.00193	0.0103	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—PRLHR—pancreatic cancer	0.00188	0.01	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.00187	0.00995	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CNR2—pancreatic cancer	0.00178	0.00949	CbGpPWpGaD
Raltegravir—CCR1—Chemokine receptors bind chemokines—CXCL8—pancreatic cancer	0.0017	0.00905	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CNR2—pancreatic cancer	0.00165	0.0088	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—SST—pancreatic cancer	0.00164	0.00874	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CCKAR—pancreatic cancer	0.00162	0.00866	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—SSTR3—pancreatic cancer	0.00159	0.0085	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—SSTR1—pancreatic cancer	0.00153	0.00815	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—PPY—pancreatic cancer	0.0015	0.00799	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—SSTR2—pancreatic cancer	0.00147	0.00785	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.00145	0.00774	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCKBR—pancreatic cancer	0.00142	0.00758	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.00141	0.00754	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—AHR—pancreatic cancer	0.0014	0.00748	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—AGTR1—pancreatic cancer	0.00139	0.00744	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.00139	0.00742	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—SST—pancreatic cancer	0.00138	0.00738	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—NFE2L2—pancreatic cancer	0.00137	0.00729	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CNR1—pancreatic cancer	0.00128	0.00681	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—CNR1—pancreatic cancer	0.00119	0.00632	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—SCT—pancreatic cancer	0.00116	0.00618	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCK—pancreatic cancer	0.00111	0.00589	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.0011	0.00587	CbGpPWpGaD
Raltegravir—CCR1—GPCRs, Class A Rhodopsin-like—AGTR1—pancreatic cancer	0.00109	0.00582	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GLP1R—pancreatic cancer	0.00108	0.00574	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CNR2—pancreatic cancer	0.00108	0.00574	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CCKAR—pancreatic cancer	0.00106	0.00565	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.00102	0.00541	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—SHH—pancreatic cancer	0.000966	0.00515	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PRLHR—pancreatic cancer	0.000963	0.00513	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—IAPP—pancreatic cancer	0.000954	0.00509	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	0.000935	0.00499	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—PTHLH—pancreatic cancer	0.000916	0.00488	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—PTCH1—pancreatic cancer	0.000916	0.00488	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—SSTR3—pancreatic cancer	0.000901	0.0048	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GDI1—pancreatic cancer	0.000882	0.0047	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GDI2—pancreatic cancer	0.000882	0.0047	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—SSTR1—pancreatic cancer	0.000864	0.00461	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PPY—pancreatic cancer	0.000847	0.00452	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—SST—pancreatic cancer	0.000838	0.00447	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—SSTR2—pancreatic cancer	0.000832	0.00443	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—SSTR3—pancreatic cancer	0.000818	0.00436	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CCKBR—pancreatic cancer	0.000803	0.00428	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—SSTR1—pancreatic cancer	0.000785	0.00418	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CNR1—pancreatic cancer	0.000773	0.00412	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PPY—pancreatic cancer	0.00077	0.0041	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—HES1—pancreatic cancer	0.000762	0.00406	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—SSTR2—pancreatic cancer	0.000755	0.00403	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—GCG—pancreatic cancer	0.000747	0.00398	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCKBR—pancreatic cancer	0.000729	0.00389	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—AGTR1—pancreatic cancer	0.000712	0.0038	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GAST—pancreatic cancer	0.000691	0.00368	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—SCT—pancreatic cancer	0.000655	0.00349	CbGpPWpGaD
Raltegravir—CCR1—Peptide ligand-binding receptors—CXCL8—pancreatic cancer	0.000639	0.00341	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GAST—pancreatic cancer	0.000627	0.00334	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CCK—pancreatic cancer	0.000625	0.00333	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CNR2—pancreatic cancer	0.000609	0.00325	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GLP1R—pancreatic cancer	0.000609	0.00325	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CCKAR—pancreatic cancer	0.000599	0.00319	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—SCT—pancreatic cancer	0.000595	0.00317	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PRLHR—pancreatic cancer	0.000569	0.00303	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCK—pancreatic cancer	0.000567	0.00302	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CNR2—pancreatic cancer	0.000553	0.00295	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GLP1R—pancreatic cancer	0.000553	0.00295	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CCKAR—pancreatic cancer	0.000544	0.0029	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—NFE2L2—pancreatic cancer	0.000543	0.00289	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—IAPP—pancreatic cancer	0.000539	0.00287	CbGpPWpGaD
Raltegravir—CCR1—G alpha (i) signalling events—CXCL8—pancreatic cancer	0.000539	0.00287	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ZNRF3—pancreatic cancer	0.000535	0.00285	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—ACVR1B—pancreatic cancer	0.000535	0.00285	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—TGFA—pancreatic cancer	0.000518	0.00276	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000518	0.00276	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—SLC2A2—pancreatic cancer	0.000507	0.0027	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—SHH—pancreatic cancer	0.000496	0.00264	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—IAPP—pancreatic cancer	0.00049	0.00261	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SSTR3—pancreatic cancer	0.000483	0.00258	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—DTX1—pancreatic cancer	0.000483	0.00258	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—SST—pancreatic cancer	0.000473	0.00252	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PTCH1—pancreatic cancer	0.00047	0.00251	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PTHLH—pancreatic cancer	0.00047	0.00251	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SSTR1—pancreatic cancer	0.000464	0.00247	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PPY—pancreatic cancer	0.000455	0.00242	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SSTR2—pancreatic cancer	0.000446	0.00238	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CNR1—pancreatic cancer	0.000437	0.00233	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCKBR—pancreatic cancer	0.000431	0.0023	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—SST—pancreatic cancer	0.00043	0.00229	CbGpPWpGaD
Raltegravir—CCR1—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000429	0.00229	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—GCG—pancreatic cancer	0.000422	0.00225	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—DTX4—pancreatic cancer	0.000405	0.00216	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GLI1—pancreatic cancer	0.000405	0.00216	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000403	0.00215	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—CNR1—pancreatic cancer	0.000397	0.00212	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000394	0.0021	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NRP1—pancreatic cancer	0.000394	0.0021	CbGpPWpGaD
Raltegravir—UGT1A1—NRF2 pathway—HSPA1A—pancreatic cancer	0.00039	0.00208	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—GCG—pancreatic cancer	0.000383	0.00204	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HEY2—pancreatic cancer	0.000379	0.00202	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GAST—pancreatic cancer	0.000371	0.00198	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—AGTR1—pancreatic cancer	0.000366	0.00195	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SCT—pancreatic cancer	0.000351	0.00187	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HEY1—pancreatic cancer	0.000351	0.00187	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—pancreatic cancer	0.000345	0.00184	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCK—pancreatic cancer	0.000335	0.00179	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CNR2—pancreatic cancer	0.000327	0.00174	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GLP1R—pancreatic cancer	0.000327	0.00174	CbGpPWpGaD
Raltegravir—CCR1—GPCR ligand binding—CXCL8—pancreatic cancer	0.000326	0.00174	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CCKAR—pancreatic cancer	0.000321	0.00171	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JAG2—pancreatic cancer	0.000312	0.00166	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—pancreatic cancer	0.000309	0.00165	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—MEN1—pancreatic cancer	0.000307	0.00164	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—pancreatic cancer	0.000303	0.00161	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SHH—pancreatic cancer	0.000293	0.00156	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOTCH4—pancreatic cancer	0.000291	0.00155	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—IAPP—pancreatic cancer	0.000289	0.00154	CbGpPWpGaD
Raltegravir—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—pancreatic cancer	0.000288	0.00154	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTHLH—pancreatic cancer	0.000278	0.00148	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTCH1—pancreatic cancer	0.000278	0.00148	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SST—pancreatic cancer	0.000254	0.00135	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.00025	0.00134	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—JAG1—pancreatic cancer	0.000249	0.00133	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NOTCH3—pancreatic cancer	0.000248	0.00132	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—CNR1—pancreatic cancer	0.000234	0.00125	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000227	0.00121	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—GCG—pancreatic cancer	0.000226	0.00121	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.00022	0.00117	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AGTR1—pancreatic cancer	0.000216	0.00115	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—STK11—pancreatic cancer	0.000213	0.00113	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CD—pancreatic cancer	0.0002	0.00107	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000192	0.00102	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—SMAD4—pancreatic cancer	0.000186	0.000994	CbGpPWpGaD
Raltegravir—CCR1—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000184	0.000983	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—HES1—pancreatic cancer	0.000182	0.00097	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000174	0.000929	CbGpPWpGaD
Raltegravir—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000173	0.000599	CcSEcCtD
Raltegravir—Breast disorder—Doxorubicin—pancreatic cancer	0.000171	0.000593	CcSEcCtD
Raltegravir—Body temperature increased—Irinotecan—pancreatic cancer	0.000171	0.000591	CcSEcCtD
Raltegravir—Abdominal pain—Irinotecan—pancreatic cancer	0.000171	0.000591	CcSEcCtD
Raltegravir—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	0.000171	0.000591	CcSEcCtD
Raltegravir—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000171	0.00059	CcSEcCtD
Raltegravir—Bronchitis—Epirubicin—pancreatic cancer	0.00017	0.00059	CcSEcCtD
Raltegravir—Nasopharyngitis—Doxorubicin—pancreatic cancer	0.00017	0.000587	CcSEcCtD
Raltegravir—Anaemia—Docetaxel—pancreatic cancer	0.000169	0.000585	CcSEcCtD
Raltegravir—Gastritis—Doxorubicin—pancreatic cancer	0.000168	0.000581	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—CXCL8—pancreatic cancer	0.000167	0.000893	CbGpPWpGaD
Raltegravir—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	0.000167	0.000579	CcSEcCtD
Raltegravir—Vomiting—Sunitinib—pancreatic cancer	0.000167	0.000577	CcSEcCtD
Raltegravir—Body temperature increased—Gemcitabine—pancreatic cancer	0.000166	0.000576	CcSEcCtD
Raltegravir—Neutropenia—Epirubicin—pancreatic cancer	0.000166	0.000573	CcSEcCtD
Raltegravir—Rash—Sunitinib—pancreatic cancer	0.000165	0.000572	CcSEcCtD
Raltegravir—Dermatitis—Sunitinib—pancreatic cancer	0.000165	0.000572	CcSEcCtD
Raltegravir—Abdominal distension—Doxorubicin—pancreatic cancer	0.000165	0.000571	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000165	0.00057	CcSEcCtD
Raltegravir—Urticaria—Fluorouracil—pancreatic cancer	0.000164	0.000569	CcSEcCtD
Raltegravir—Headache—Sunitinib—pancreatic cancer	0.000164	0.000569	CcSEcCtD
Raltegravir—Influenza—Doxorubicin—pancreatic cancer	0.000164	0.000567	CcSEcCtD
Raltegravir—Body temperature increased—Fluorouracil—pancreatic cancer	0.000164	0.000566	CcSEcCtD
Raltegravir—Eosinophilia—Doxorubicin—pancreatic cancer	0.000162	0.000562	CcSEcCtD
Raltegravir—Palpitations—Docetaxel—pancreatic cancer	0.000162	0.00056	CcSEcCtD
Raltegravir—Weight increased—Epirubicin—pancreatic cancer	0.000161	0.000558	CcSEcCtD
Raltegravir—Weight decreased—Epirubicin—pancreatic cancer	0.00016	0.000555	CcSEcCtD
Raltegravir—Hyperglycaemia—Epirubicin—pancreatic cancer	0.00016	0.000553	CcSEcCtD
Raltegravir—Cough—Docetaxel—pancreatic cancer	0.00016	0.000553	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TERT—pancreatic cancer	0.000159	0.00085	CbGpPWpGaD
Raltegravir—Hypersensitivity—Irinotecan—pancreatic cancer	0.000159	0.000551	CcSEcCtD
Raltegravir—Hypertension—Docetaxel—pancreatic cancer	0.000158	0.000547	CcSEcCtD
Raltegravir—Infestation—Epirubicin—pancreatic cancer	0.000158	0.000547	CcSEcCtD
Raltegravir—Infestation NOS—Epirubicin—pancreatic cancer	0.000158	0.000547	CcSEcCtD
Raltegravir—Bronchitis—Doxorubicin—pancreatic cancer	0.000158	0.000546	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000157	0.000542	CcSEcCtD
Raltegravir—Myalgia—Docetaxel—pancreatic cancer	0.000156	0.000539	CcSEcCtD
Raltegravir—Chest pain—Docetaxel—pancreatic cancer	0.000156	0.000539	CcSEcCtD
Raltegravir—Arthralgia—Docetaxel—pancreatic cancer	0.000156	0.000539	CcSEcCtD
Raltegravir—Nausea—Sunitinib—pancreatic cancer	0.000156	0.000539	CcSEcCtD
Raltegravir—Renal failure—Epirubicin—pancreatic cancer	0.000155	0.000537	CcSEcCtD
Raltegravir—Asthenia—Irinotecan—pancreatic cancer	0.000155	0.000537	CcSEcCtD
Raltegravir—Neuropathy peripheral—Epirubicin—pancreatic cancer	0.000155	0.000536	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	0.000155	0.000536	CcSEcCtD
Raltegravir—Neutropenia—Doxorubicin—pancreatic cancer	0.000153	0.00053	CcSEcCtD
Raltegravir—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000153	0.000528	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—HIF1A—pancreatic cancer	0.000153	0.000813	CbGpPWpGaD
Raltegravir—Dry mouth—Docetaxel—pancreatic cancer	0.000152	0.000527	CcSEcCtD
Raltegravir—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000152	0.000527	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TSC2—pancreatic cancer	0.000152	0.000811	CbGpPWpGaD
Raltegravir—Asthenia—Gemcitabine—pancreatic cancer	0.000151	0.000523	CcSEcCtD
Raltegravir—Haematuria—Epirubicin—pancreatic cancer	0.000151	0.000521	CcSEcCtD
Raltegravir—Confusional state—Docetaxel—pancreatic cancer	0.000151	0.000521	CcSEcCtD
Raltegravir—Hepatobiliary disease—Epirubicin—pancreatic cancer	0.000149	0.000517	CcSEcCtD
Raltegravir—Weight increased—Doxorubicin—pancreatic cancer	0.000149	0.000516	CcSEcCtD
Raltegravir—Epistaxis—Epirubicin—pancreatic cancer	0.000149	0.000516	CcSEcCtD
Raltegravir—Pruritus—Gemcitabine—pancreatic cancer	0.000149	0.000515	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—APOE—pancreatic cancer	0.000149	0.000794	CbGpPWpGaD
Raltegravir—Infection—Docetaxel—pancreatic cancer	0.000148	0.000514	CcSEcCtD
Raltegravir—Weight decreased—Doxorubicin—pancreatic cancer	0.000148	0.000513	CcSEcCtD
Raltegravir—Hyperglycaemia—Doxorubicin—pancreatic cancer	0.000148	0.000512	CcSEcCtD
Raltegravir—Diarrhoea—Irinotecan—pancreatic cancer	0.000148	0.000512	CcSEcCtD
Raltegravir—Nervous system disorder—Docetaxel—pancreatic cancer	0.000147	0.000507	CcSEcCtD
Raltegravir—Pruritus—Fluorouracil—pancreatic cancer	0.000146	0.000507	CcSEcCtD
Raltegravir—Thrombocytopenia—Docetaxel—pancreatic cancer	0.000146	0.000506	CcSEcCtD
Raltegravir—Infestation—Doxorubicin—pancreatic cancer	0.000146	0.000506	CcSEcCtD
Raltegravir—Infestation NOS—Doxorubicin—pancreatic cancer	0.000146	0.000506	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—KDR—pancreatic cancer	0.000146	0.000778	CbGpPWpGaD
Raltegravir—Skin disorder—Docetaxel—pancreatic cancer	0.000145	0.000502	CcSEcCtD
Raltegravir—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000145	0.000501	CcSEcCtD
Raltegravir—Diarrhoea—Gemcitabine—pancreatic cancer	0.000144	0.000498	CcSEcCtD
Raltegravir—Renal failure—Doxorubicin—pancreatic cancer	0.000144	0.000497	CcSEcCtD
Raltegravir—Neuropathy peripheral—Doxorubicin—pancreatic cancer	0.000143	0.000496	CcSEcCtD
Raltegravir—Dizziness—Irinotecan—pancreatic cancer	0.000143	0.000494	CcSEcCtD
Raltegravir—Hepatitis—Epirubicin—pancreatic cancer	0.000142	0.000491	CcSEcCtD
Raltegravir—Diarrhoea—Fluorouracil—pancreatic cancer	0.000142	0.00049	CcSEcCtD
Raltegravir—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000141	0.000488	CcSEcCtD
Raltegravir—Urinary tract disorder—Epirubicin—pancreatic cancer	0.00014	0.000485	CcSEcCtD
Raltegravir—Oedema peripheral—Epirubicin—pancreatic cancer	0.00014	0.000483	CcSEcCtD
Raltegravir—Haematuria—Doxorubicin—pancreatic cancer	0.000139	0.000482	CcSEcCtD
Raltegravir—Connective tissue disorder—Epirubicin—pancreatic cancer	0.000139	0.000482	CcSEcCtD
Raltegravir—Urethral disorder—Epirubicin—pancreatic cancer	0.000139	0.000481	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NFKBIA—pancreatic cancer	0.000139	0.00074	CbGpPWpGaD
Raltegravir—Hepatobiliary disease—Doxorubicin—pancreatic cancer	0.000138	0.000478	CcSEcCtD
Raltegravir—Epistaxis—Doxorubicin—pancreatic cancer	0.000138	0.000477	CcSEcCtD
Raltegravir—Vomiting—Irinotecan—pancreatic cancer	0.000137	0.000475	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—NOTCH1—pancreatic cancer	0.000137	0.000733	CbGpPWpGaD
Raltegravir—Dizziness—Fluorouracil—pancreatic cancer	0.000137	0.000474	CcSEcCtD
Raltegravir—Visual impairment—Epirubicin—pancreatic cancer	0.000137	0.000473	CcSEcCtD
Raltegravir—Rash—Irinotecan—pancreatic cancer	0.000136	0.000471	CcSEcCtD
Raltegravir—Dermatitis—Irinotecan—pancreatic cancer	0.000136	0.000471	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000136	0.000471	CcSEcCtD
Raltegravir—Headache—Irinotecan—pancreatic cancer	0.000135	0.000468	CcSEcCtD
Raltegravir—Insomnia—Docetaxel—pancreatic cancer	0.000135	0.000468	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PIK3CG—pancreatic cancer	0.000134	0.000716	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—NRAS—pancreatic cancer	0.000134	0.000716	CbGpPWpGaD
Raltegravir—Paraesthesia—Docetaxel—pancreatic cancer	0.000134	0.000464	CcSEcCtD
Raltegravir—Erythema multiforme—Epirubicin—pancreatic cancer	0.000134	0.000464	CcSEcCtD
Raltegravir—Vomiting—Gemcitabine—pancreatic cancer	0.000134	0.000463	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—PRSS1—pancreatic cancer	0.000133	0.000711	CbGpPWpGaD
Raltegravir—Somnolence—Docetaxel—pancreatic cancer	0.000133	0.00046	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—EGF—pancreatic cancer	0.000133	0.000708	CbGpPWpGaD
Raltegravir—Rash—Gemcitabine—pancreatic cancer	0.000133	0.000459	CcSEcCtD
Raltegravir—Dermatitis—Gemcitabine—pancreatic cancer	0.000133	0.000459	CcSEcCtD
Raltegravir—Eye disorder—Epirubicin—pancreatic cancer	0.000133	0.000459	CcSEcCtD
Raltegravir—Tinnitus—Epirubicin—pancreatic cancer	0.000132	0.000458	CcSEcCtD
Raltegravir—Headache—Gemcitabine—pancreatic cancer	0.000132	0.000456	CcSEcCtD
Raltegravir—Cardiac disorder—Epirubicin—pancreatic cancer	0.000132	0.000455	CcSEcCtD
Raltegravir—Vomiting—Fluorouracil—pancreatic cancer	0.000132	0.000455	CcSEcCtD
Raltegravir—Dyspepsia—Docetaxel—pancreatic cancer	0.000132	0.000455	CcSEcCtD
Raltegravir—Hepatitis—Doxorubicin—pancreatic cancer	0.000131	0.000454	CcSEcCtD
Raltegravir—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.000131	0.000452	CcSEcCtD
Raltegravir—Rash—Fluorouracil—pancreatic cancer	0.000131	0.000452	CcSEcCtD
Raltegravir—Dermatitis—Fluorouracil—pancreatic cancer	0.00013	0.000451	CcSEcCtD
Raltegravir—Decreased appetite—Docetaxel—pancreatic cancer	0.00013	0.000449	CcSEcCtD
Raltegravir—Headache—Fluorouracil—pancreatic cancer	0.00013	0.000449	CcSEcCtD
Raltegravir—Urinary tract disorder—Doxorubicin—pancreatic cancer	0.00013	0.000448	CcSEcCtD
Raltegravir—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000129	0.000447	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000129	0.000446	CcSEcCtD
Raltegravir—Connective tissue disorder—Doxorubicin—pancreatic cancer	0.000129	0.000446	CcSEcCtD
Raltegravir—Fatigue—Docetaxel—pancreatic cancer	0.000129	0.000446	CcSEcCtD
Raltegravir—Angiopathy—Epirubicin—pancreatic cancer	0.000129	0.000445	CcSEcCtD
Raltegravir—Urethral disorder—Doxorubicin—pancreatic cancer	0.000129	0.000445	CcSEcCtD
Raltegravir—Nausea—Irinotecan—pancreatic cancer	0.000128	0.000444	CcSEcCtD
Raltegravir—Immune system disorder—Epirubicin—pancreatic cancer	0.000128	0.000443	CcSEcCtD
Raltegravir—Mediastinal disorder—Epirubicin—pancreatic cancer	0.000128	0.000442	CcSEcCtD
Raltegravir—Pain—Docetaxel—pancreatic cancer	0.000128	0.000442	CcSEcCtD
Raltegravir—Constipation—Docetaxel—pancreatic cancer	0.000128	0.000442	CcSEcCtD
Raltegravir—Chills—Epirubicin—pancreatic cancer	0.000127	0.00044	CcSEcCtD
Raltegravir—Visual impairment—Doxorubicin—pancreatic cancer	0.000127	0.000438	CcSEcCtD
Raltegravir—Alopecia—Epirubicin—pancreatic cancer	0.000125	0.000434	CcSEcCtD
Raltegravir—Nausea—Gemcitabine—pancreatic cancer	0.000125	0.000433	CcSEcCtD
Raltegravir—Mental disorder—Epirubicin—pancreatic cancer	0.000124	0.00043	CcSEcCtD
Raltegravir—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000124	0.000429	CcSEcCtD
Raltegravir—Malnutrition—Epirubicin—pancreatic cancer	0.000124	0.000427	CcSEcCtD
Raltegravir—Erythema—Epirubicin—pancreatic cancer	0.000124	0.000427	CcSEcCtD
Raltegravir—Feeling abnormal—Docetaxel—pancreatic cancer	0.000123	0.000426	CcSEcCtD
Raltegravir—Nausea—Fluorouracil—pancreatic cancer	0.000123	0.000425	CcSEcCtD
Raltegravir—Eye disorder—Doxorubicin—pancreatic cancer	0.000123	0.000424	CcSEcCtD
Raltegravir—UGT1A1—NRF2 pathway—TGFB1—pancreatic cancer	0.000123	0.000654	CbGpPWpGaD
Raltegravir—CCR1—Signaling by GPCR—EGFR—pancreatic cancer	0.000122	0.000653	CbGpPWpGaD
Raltegravir—Tinnitus—Doxorubicin—pancreatic cancer	0.000122	0.000423	CcSEcCtD
Raltegravir—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000122	0.000423	CcSEcCtD
Raltegravir—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000122	0.000421	CcSEcCtD
Raltegravir—Flatulence—Epirubicin—pancreatic cancer	0.000122	0.000421	CcSEcCtD
Raltegravir—Dysgeusia—Epirubicin—pancreatic cancer	0.000121	0.000418	CcSEcCtD
Raltegravir—Nervousness—Epirubicin—pancreatic cancer	0.00012	0.000415	CcSEcCtD
Raltegravir—Back pain—Epirubicin—pancreatic cancer	0.000119	0.000413	CcSEcCtD
Raltegravir—Angiopathy—Doxorubicin—pancreatic cancer	0.000119	0.000412	CcSEcCtD
Raltegravir—Immune system disorder—Doxorubicin—pancreatic cancer	0.000119	0.00041	CcSEcCtD
Raltegravir—Mediastinal disorder—Doxorubicin—pancreatic cancer	0.000118	0.000409	CcSEcCtD
Raltegravir—Body temperature increased—Docetaxel—pancreatic cancer	0.000118	0.000409	CcSEcCtD
Raltegravir—Abdominal pain—Docetaxel—pancreatic cancer	0.000118	0.000409	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PIK3CD—pancreatic cancer	0.000118	0.00063	CbGpPWpGaD
Raltegravir—Chills—Doxorubicin—pancreatic cancer	0.000118	0.000407	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—PIK3CA—pancreatic cancer	0.000117	0.000624	CbGpPWpGaD
Raltegravir—Alopecia—Doxorubicin—pancreatic cancer	0.000116	0.000401	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—KRAS—pancreatic cancer	0.000116	0.000617	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—ARG2—pancreatic cancer	0.000116	0.000616	CbGpPWpGaD
Raltegravir—Mental disorder—Doxorubicin—pancreatic cancer	0.000115	0.000398	CcSEcCtD
Raltegravir—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000115	0.000396	CcSEcCtD
Raltegravir—Malnutrition—Doxorubicin—pancreatic cancer	0.000114	0.000395	CcSEcCtD
Raltegravir—Erythema—Doxorubicin—pancreatic cancer	0.000114	0.000395	CcSEcCtD
Raltegravir—Anaemia—Epirubicin—pancreatic cancer	0.000114	0.000395	CcSEcCtD
Raltegravir—Agitation—Epirubicin—pancreatic cancer	0.000113	0.000393	CcSEcCtD
Raltegravir—Flatulence—Doxorubicin—pancreatic cancer	0.000113	0.00039	CcSEcCtD
Raltegravir—Dysgeusia—Doxorubicin—pancreatic cancer	0.000112	0.000387	CcSEcCtD
Raltegravir—Malaise—Epirubicin—pancreatic cancer	0.000111	0.000385	CcSEcCtD
Raltegravir—Nervousness—Doxorubicin—pancreatic cancer	0.000111	0.000384	CcSEcCtD
Raltegravir—Vertigo—Epirubicin—pancreatic cancer	0.000111	0.000384	CcSEcCtD
Raltegravir—Back pain—Doxorubicin—pancreatic cancer	0.000111	0.000382	CcSEcCtD
Raltegravir—Hypersensitivity—Docetaxel—pancreatic cancer	0.00011	0.000381	CcSEcCtD
Raltegravir—Palpitations—Epirubicin—pancreatic cancer	0.000109	0.000378	CcSEcCtD
Raltegravir—Cough—Epirubicin—pancreatic cancer	0.000108	0.000373	CcSEcCtD
Raltegravir—Asthenia—Docetaxel—pancreatic cancer	0.000107	0.000371	CcSEcCtD
Raltegravir—Hypertension—Epirubicin—pancreatic cancer	0.000107	0.000369	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—PIK3CA—pancreatic cancer	0.000106	0.000566	CbGpPWpGaD
Raltegravir—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000106	0.000367	CcSEcCtD
Raltegravir—Pruritus—Docetaxel—pancreatic cancer	0.000106	0.000366	CcSEcCtD
Raltegravir—Anaemia—Doxorubicin—pancreatic cancer	0.000106	0.000365	CcSEcCtD
Raltegravir—Myalgia—Epirubicin—pancreatic cancer	0.000105	0.000364	CcSEcCtD
Raltegravir—Chest pain—Epirubicin—pancreatic cancer	0.000105	0.000364	CcSEcCtD
Raltegravir—Arthralgia—Epirubicin—pancreatic cancer	0.000105	0.000364	CcSEcCtD
Raltegravir—Agitation—Doxorubicin—pancreatic cancer	0.000105	0.000363	CcSEcCtD
Raltegravir—Anxiety—Epirubicin—pancreatic cancer	0.000105	0.000362	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	0.000104	0.000361	CcSEcCtD
Raltegravir—Discomfort—Epirubicin—pancreatic cancer	0.000104	0.000359	CcSEcCtD
Raltegravir—Malaise—Doxorubicin—pancreatic cancer	0.000103	0.000356	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PIK3CB—pancreatic cancer	0.000103	0.000549	CbGpPWpGaD
Raltegravir—Dry mouth—Epirubicin—pancreatic cancer	0.000103	0.000356	CcSEcCtD
Raltegravir—Vertigo—Doxorubicin—pancreatic cancer	0.000103	0.000355	CcSEcCtD
Raltegravir—Diarrhoea—Docetaxel—pancreatic cancer	0.000102	0.000354	CcSEcCtD
Raltegravir—Confusional state—Epirubicin—pancreatic cancer	0.000102	0.000352	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—TYMP—pancreatic cancer	0.000101	0.000539	CbGpPWpGaD
Raltegravir—Palpitations—Doxorubicin—pancreatic cancer	0.000101	0.000349	CcSEcCtD
Raltegravir—Infection—Epirubicin—pancreatic cancer	0.0001	0.000346	CcSEcCtD
Raltegravir—Cough—Doxorubicin—pancreatic cancer	9.97e-05	0.000345	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CXCL8—pancreatic cancer	9.89e-05	0.000528	CbGpPWpGaD
Raltegravir—Nervous system disorder—Epirubicin—pancreatic cancer	9.88e-05	0.000342	CcSEcCtD
Raltegravir—Dizziness—Docetaxel—pancreatic cancer	9.88e-05	0.000342	CcSEcCtD
Raltegravir—Thrombocytopenia—Epirubicin—pancreatic cancer	9.87e-05	0.000341	CcSEcCtD
Raltegravir—Hypertension—Doxorubicin—pancreatic cancer	9.87e-05	0.000341	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—HRAS—pancreatic cancer	9.83e-05	0.000524	CbGpPWpGaD
Raltegravir—Skin disorder—Epirubicin—pancreatic cancer	9.79e-05	0.000339	CcSEcCtD
Raltegravir—Hyperhidrosis—Epirubicin—pancreatic cancer	9.74e-05	0.000337	CcSEcCtD
Raltegravir—Myalgia—Doxorubicin—pancreatic cancer	9.73e-05	0.000337	CcSEcCtD
Raltegravir—Arthralgia—Doxorubicin—pancreatic cancer	9.73e-05	0.000337	CcSEcCtD
Raltegravir—Chest pain—Doxorubicin—pancreatic cancer	9.73e-05	0.000337	CcSEcCtD
Raltegravir—Anxiety—Doxorubicin—pancreatic cancer	9.7e-05	0.000335	CcSEcCtD
Raltegravir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	9.66e-05	0.000334	CcSEcCtD
Raltegravir—Discomfort—Doxorubicin—pancreatic cancer	9.61e-05	0.000332	CcSEcCtD
Raltegravir—CCR1—GPCR downstream signaling—AKT1—pancreatic cancer	9.56e-05	0.00051	CbGpPWpGaD
Raltegravir—Dry mouth—Doxorubicin—pancreatic cancer	9.51e-05	0.000329	CcSEcCtD
Raltegravir—Vomiting—Docetaxel—pancreatic cancer	9.5e-05	0.000329	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CASP3—pancreatic cancer	9.47e-05	0.000505	CbGpPWpGaD
Raltegravir—Rash—Docetaxel—pancreatic cancer	9.42e-05	0.000326	CcSEcCtD
Raltegravir—Dermatitis—Docetaxel—pancreatic cancer	9.41e-05	0.000326	CcSEcCtD
Raltegravir—Confusional state—Doxorubicin—pancreatic cancer	9.4e-05	0.000325	CcSEcCtD
Raltegravir—Headache—Docetaxel—pancreatic cancer	9.36e-05	0.000324	CcSEcCtD
Raltegravir—Infection—Doxorubicin—pancreatic cancer	9.27e-05	0.00032	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CCND1—pancreatic cancer	9.22e-05	0.000491	CbGpPWpGaD
Raltegravir—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	9.18e-05	0.000318	CcSEcCtD
Raltegravir—Nervous system disorder—Doxorubicin—pancreatic cancer	9.15e-05	0.000316	CcSEcCtD
Raltegravir—Thrombocytopenia—Doxorubicin—pancreatic cancer	9.13e-05	0.000316	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—CTNNB1—pancreatic cancer	9.13e-05	0.000487	CbGpPWpGaD
Raltegravir—Insomnia—Epirubicin—pancreatic cancer	9.12e-05	0.000315	CcSEcCtD
Raltegravir—Skin disorder—Doxorubicin—pancreatic cancer	9.06e-05	0.000313	CcSEcCtD
Raltegravir—Paraesthesia—Epirubicin—pancreatic cancer	9.05e-05	0.000313	CcSEcCtD
Raltegravir—Hyperhidrosis—Doxorubicin—pancreatic cancer	9.02e-05	0.000312	CcSEcCtD
Raltegravir—Somnolence—Epirubicin—pancreatic cancer	8.96e-05	0.00031	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MMP9—pancreatic cancer	8.95e-05	0.000477	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—PTEN—pancreatic cancer	8.9e-05	0.000474	CbGpPWpGaD
Raltegravir—Nausea—Docetaxel—pancreatic cancer	8.88e-05	0.000307	CcSEcCtD
Raltegravir—Dyspepsia—Epirubicin—pancreatic cancer	8.87e-05	0.000307	CcSEcCtD
Raltegravir—Decreased appetite—Epirubicin—pancreatic cancer	8.76e-05	0.000303	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Epirubicin—pancreatic cancer	8.7e-05	0.000301	CcSEcCtD
Raltegravir—Fatigue—Epirubicin—pancreatic cancer	8.69e-05	0.000301	CcSEcCtD
Raltegravir—CCR1—Signaling by GPCR—AKT1—pancreatic cancer	8.68e-05	0.000463	CbGpPWpGaD
Raltegravir—Pain—Epirubicin—pancreatic cancer	8.62e-05	0.000298	CcSEcCtD
Raltegravir—Constipation—Epirubicin—pancreatic cancer	8.62e-05	0.000298	CcSEcCtD
Raltegravir—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	8.5e-05	0.000294	CcSEcCtD
Raltegravir—Insomnia—Doxorubicin—pancreatic cancer	8.44e-05	0.000292	CcSEcCtD
Raltegravir—Paraesthesia—Doxorubicin—pancreatic cancer	8.37e-05	0.00029	CcSEcCtD
Raltegravir—Feeling abnormal—Epirubicin—pancreatic cancer	8.31e-05	0.000287	CcSEcCtD
Raltegravir—Somnolence—Doxorubicin—pancreatic cancer	8.29e-05	0.000287	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—SRC—pancreatic cancer	8.25e-05	0.00044	CbGpPWpGaD
Raltegravir—Gastrointestinal pain—Epirubicin—pancreatic cancer	8.24e-05	0.000285	CcSEcCtD
Raltegravir—Dyspepsia—Doxorubicin—pancreatic cancer	8.21e-05	0.000284	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—GLP1R—pancreatic cancer	8.14e-05	0.000434	CbGpPWpGaD
Raltegravir—Decreased appetite—Doxorubicin—pancreatic cancer	8.11e-05	0.00028	CcSEcCtD
Raltegravir—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	8.05e-05	0.000279	CcSEcCtD
Raltegravir—Fatigue—Doxorubicin—pancreatic cancer	8.04e-05	0.000278	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—VEGFA—pancreatic cancer	8.04e-05	0.000428	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—DPYD—pancreatic cancer	8.01e-05	0.000427	CbGpPWpGaD
Raltegravir—Urticaria—Epirubicin—pancreatic cancer	8.01e-05	0.000277	CcSEcCtD
Raltegravir—Constipation—Doxorubicin—pancreatic cancer	7.98e-05	0.000276	CcSEcCtD
Raltegravir—Pain—Doxorubicin—pancreatic cancer	7.98e-05	0.000276	CcSEcCtD
Raltegravir—Body temperature increased—Epirubicin—pancreatic cancer	7.97e-05	0.000276	CcSEcCtD
Raltegravir—Abdominal pain—Epirubicin—pancreatic cancer	7.97e-05	0.000276	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—STAT3—pancreatic cancer	7.96e-05	0.000424	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—NRAS—pancreatic cancer	7.94e-05	0.000423	CbGpPWpGaD
Raltegravir—Feeling abnormal—Doxorubicin—pancreatic cancer	7.69e-05	0.000266	CcSEcCtD
Raltegravir—Gastrointestinal pain—Doxorubicin—pancreatic cancer	7.63e-05	0.000264	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—SLC2A2—pancreatic cancer	7.6e-05	0.000405	CbGpPWpGaD
Raltegravir—Hypersensitivity—Epirubicin—pancreatic cancer	7.43e-05	0.000257	CcSEcCtD
Raltegravir—Urticaria—Doxorubicin—pancreatic cancer	7.41e-05	0.000256	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—MYC—pancreatic cancer	7.39e-05	0.000394	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—TGFB1—pancreatic cancer	7.38e-05	0.000393	CbGpPWpGaD
Raltegravir—Body temperature increased—Doxorubicin—pancreatic cancer	7.37e-05	0.000255	CcSEcCtD
Raltegravir—Abdominal pain—Doxorubicin—pancreatic cancer	7.37e-05	0.000255	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—EGFR—pancreatic cancer	7.23e-05	0.000386	CbGpPWpGaD
Raltegravir—Asthenia—Epirubicin—pancreatic cancer	7.23e-05	0.00025	CcSEcCtD
Raltegravir—Pruritus—Epirubicin—pancreatic cancer	7.13e-05	0.000247	CcSEcCtD
Raltegravir—Diarrhoea—Epirubicin—pancreatic cancer	6.9e-05	0.000239	CcSEcCtD
Raltegravir—Hypersensitivity—Doxorubicin—pancreatic cancer	6.87e-05	0.000238	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—KRAS—pancreatic cancer	6.83e-05	0.000364	CbGpPWpGaD
Raltegravir—Asthenia—Doxorubicin—pancreatic cancer	6.69e-05	0.000231	CcSEcCtD
Raltegravir—Dizziness—Epirubicin—pancreatic cancer	6.67e-05	0.000231	CcSEcCtD
Raltegravir—Pruritus—Doxorubicin—pancreatic cancer	6.6e-05	0.000228	CcSEcCtD
Raltegravir—Vomiting—Epirubicin—pancreatic cancer	6.41e-05	0.000222	CcSEcCtD
Raltegravir—Diarrhoea—Doxorubicin—pancreatic cancer	6.38e-05	0.000221	CcSEcCtD
Raltegravir—Rash—Epirubicin—pancreatic cancer	6.36e-05	0.00022	CcSEcCtD
Raltegravir—Dermatitis—Epirubicin—pancreatic cancer	6.35e-05	0.00022	CcSEcCtD
Raltegravir—Headache—Epirubicin—pancreatic cancer	6.31e-05	0.000218	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—PIK3CA—pancreatic cancer	6.28e-05	0.000335	CbGpPWpGaD
Raltegravir—Dizziness—Doxorubicin—pancreatic cancer	6.17e-05	0.000213	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—TP53—pancreatic cancer	6.07e-05	0.000324	CbGpPWpGaD
Raltegravir—Nausea—Epirubicin—pancreatic cancer	5.99e-05	0.000207	CcSEcCtD
Raltegravir—Vomiting—Doxorubicin—pancreatic cancer	5.93e-05	0.000205	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—CD44—pancreatic cancer	5.89e-05	0.000314	CbGpPWpGaD
Raltegravir—Rash—Doxorubicin—pancreatic cancer	5.88e-05	0.000203	CcSEcCtD
Raltegravir—Dermatitis—Doxorubicin—pancreatic cancer	5.87e-05	0.000203	CcSEcCtD
Raltegravir—Headache—Doxorubicin—pancreatic cancer	5.84e-05	0.000202	CcSEcCtD
Raltegravir—CCR1—Signaling Pathways—HRAS—pancreatic cancer	5.81e-05	0.00031	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—GCG—pancreatic cancer	5.64e-05	0.000301	CbGpPWpGaD
Raltegravir—Nausea—Doxorubicin—pancreatic cancer	5.54e-05	0.000192	CcSEcCtD
Raltegravir—UGT1A1—Metabolism—STK11—pancreatic cancer	5.31e-05	0.000283	CbGpPWpGaD
Raltegravir—CCR1—Signaling Pathways—AKT1—pancreatic cancer	5.13e-05	0.000273	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—TYMS—pancreatic cancer	4.56e-05	0.000243	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—APOE—pancreatic cancer	3.71e-05	0.000198	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CG—pancreatic cancer	3.35e-05	0.000179	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PPARG—pancreatic cancer	3.23e-05	0.000172	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CD—pancreatic cancer	2.95e-05	0.000157	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CB—pancreatic cancer	2.57e-05	0.000137	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTGS2—pancreatic cancer	2.54e-05	0.000136	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PTEN—pancreatic cancer	2.22e-05	0.000118	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—PIK3CA—pancreatic cancer	1.56e-05	8.34e-05	CbGpPWpGaD
Raltegravir—UGT1A1—Metabolism—AKT1—pancreatic cancer	1.28e-05	6.82e-05	CbGpPWpGaD
